A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet

Eur Respir J. 2023 Apr 20;61(4):2300270. doi: 10.1183/13993003.00270-2023. Print 2023 Apr.

Authors

Mattia Nigro^{1

2}, James D Chalmers³, Stefano Aliberti^{4

2}

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
² IRCCS Humanitas Research Hospital, Respiratory Unit, Rozzano, Milan, Italy.
³ Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
⁴ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy stefano.aliberti@hunimed.eu.

Abstract

Other steroids are currently not superior to dexamethasone 6 mg in COVID-19 patients with acute respiratory failure https://bit.ly/3YUkc8G

Publication types

Editorial
Comment

MeSH terms

Adrenal Cortex Hormones / therapeutic use
COVID-19 Drug Treatment
COVID-19*
Dexamethasone
Humans
Methylprednisolone

Substances

Methylprednisolone
Adrenal Cortex Hormones
Dexamethasone